Dize Pharmaceutical: Multiple recent research advances in hematologic malignancies selected for EHA annual meeting

Dizepharmaceutical announcement, the company will announce the latest clinical data of 8 studies in its blood tumor pipeline at the 2025 European Hematology Association Annual Meeting and the 18th International Malignant Lymphoma Conference to be held in June this year. The company's core products, Gaurize and DZD8586, have made progress in the field of lymphoma research, receiving three oral presentations since this year's American Society of Clinical Oncology Annual Meeting. Among them, a phase II prospective multicenter clinical study, JACKPOT26, of Gaurize's latest 2-year follow-up data was selected for this EHA conference and also received an oral presentation at the ICML conference. This study aims to evaluate the safety and efficacy of Gaurize for maintenance therapy of peripheral T-cell lymphoma in remission after first-line systemic treatment. The results of two studies on DZD8586 have been selected consecutively for international top academic conferences such as ASCO, EHA, and ICML.